Category Specific RSS

pxs-5505

Pharmaxis progresses FDA discussions, set to expand bone marrow cancer trial to treat more patients

A large cohort of patients around the world diagnosed with myelofibrosis (aka bone marrow cancer) will soon be able to…

2 years ago

Fibrosis is the simple disease process that’s more important than you think

How does a company with a lead asset cancer drug also get into dermatology?  What does blood cancer and keloid…

3 years ago

International expansion as more hospitals register for Pharmaxis’ cancer treatment trials

Clinical stage pharmaceutical company Pharmaxis (PXS: ASX) is full steam ahead with their Phase 2 clinical trial for flagship drug,…

3 years ago

Making their mark: Pharmaxis to continue clinical trials in revolutionary anti-skin scarring drug

In the wake of their oversubscribed capital raising effort, clinical stage pharmaceutical company Pharmaxis (ASX: PXS) is forging ahead with…

3 years ago

First cohort responds well to Pharmaxis cancer treatment drug – next phase of clinical trial fully subscribed

Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for…

4 years ago